Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
- Nippon Shinyaku: Sales Up 0.9% to ¥63.5 Bil. Driven by Cialis, Lunabell
June 6, 2011
- Some GE Houses to Delay Listing Actos Generics for 1 Year
June 6, 2011
- Sales Up 33.1% Driven by CMO Business: CMIC
June 6, 2011
- Sawai to Launch Actos Generics with Full Indications in June
June 6, 2011
- Cervarix Ranked No. 1 in GP Market in March: RepTrack Survey
June 6, 2011
- Towa Ready to Launch Generic Actos with Full Indications
June 6, 2011
- Daiichi Sankyo, AZ to Copromote Denosumab in Japan
June 6, 2011
- Toyota Tsusho to Represent GHL in Japan for Biosimilars Contract Manufacturing Service
June 6, 2011
- Wholesalers Were the Only Losers: Chairman Matsutani of Toho
June 6, 2011
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…